X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AT-100 (zelpultide alfa) is a recombinant version of the endogenous human SP-D, a protein essential to the lung’s immune defense in reducing inflammation and infection while modulating immune responses for the patients of Bronchopulmonary Dysplasia.
Lead Product(s): Zelpultide Alfa
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
AT-100 (zelpultide alfa) is a recombinant version of the endogenous human SP-D, a protein essential to the lung’s immune defense in reducing inflammation and infection while modulating immune response. It is being investigated in preterm infants for bronchopulmonary dysplasia.
Lead Product(s): Zelpultide Alfa
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
Zelpultide alfa (AT-100) is a novel recombinant version of the endogenous human protein hSP-D, a protein that reduces inflammation and infection in the body while modulating the immune response to break the cycle of injury and inflammation.
Lead Product(s): Zelpultide Alfa
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
In preclinical studies, AT-100 has shown to reduce inflammation and infection triggered by mechanical ventilation and oxygen support, and ultimately reduce the onset of lung damage.
Lead Product(s): rhSP-D
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Preclinical studies have shown that the human recombinant protein ,AT-100, can safely minimise inflammation and infection while modulating the immune response in a variety of respiratory diseases both inside and outside the lung.
Lead Product(s): rhSP-D
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
AT-100 is a novel human recombinant protein that has been shown in preclinical studies to reduce inflammation and infection triggered in very preterm babies by mechanical ventilation and oxygen support and ultimately reduce the onset of lung damage.
Lead Product(s): rhSP-D
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2021
Details:
Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study.
Lead Product(s): AT-100
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Celonic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 20, 2020
Details:
Airway is aiming to enter the clinic later this year with AT-100 as an investigational preventive treatment for the serious respiratory disease.
Lead Product(s): AT-100
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2020
Details:
This funding will enable clinical development of AT-100 (rhSP-D), while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.
Lead Product(s): AT-100
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $15.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
